Post-Op Radiation Safely Eliminated in Node-Negative Neck HNSCC
Elimination of radiation therapy did not alter quality-of-life outcomes.
Head and Neck Cancer
Fragmentation Pattern of Cell-Free DNA Can Reveal Cancer, Even at Early Stages
Machine learning algorithm detected 7 types of cancer in liquid biopsy and identified tissue of disease origin.
Solving the Obesity Paradox in Oncology
One potentially revolutionary hypothesis relates to the evolutionary processes involved in oncogenesis.
Age Does Not Impact Survival After Transthoracic Esophagectomy, Study Finds
Age was not a significant prognostic factor for long-term survival after transthoracic esophagectomy among patients with thoracic esophageal cancer.
Analysis Sheds Light on Bevacizumab “Reversals” in Glioblastoma
Improvements to PFS and “clinically meaningful reductions in daily corticosteroid use” were said to be linked to the addition of bevacizumab in glioblastoma.
Multidisciplinary Genetic Tumor Boards: Critical for Interpreting Tumor-Only Sequencing Results
One approach for improving recommendations based on tumor-only sequencing is use of a multidisciplinary genomic tumor board, in which researchers from a variety of backgrounds weigh in on the best way to interpret test results.
Statins May Be Beneficial After Radiation to Thorax, Head, Neck
Statin use tied to reduction in stroke incidence for cardiac patients with thorax and head or neck cancer.
Keytruda Approved for First Line Treatment of Unresectable, Recurrent HNSCC
The FDA has approved Keytruda (pembrolizumab; Merck) for first line treatment of patients with metastatic or unresectable, recurrent head and neck squamous cell carcinoma as monotherapy for patients whose tumors express PD-L1 (Combined Positive Score [CPS] ≥1) or in combination with platinum and fluorouracil (FU) regardless of PD-L1 expression.
Mouth Rinse for HPV DNA May Be Biomarker in Head, Neck Cancer
Human papillomavirus (HPV) DNA detected from a mouth rinse may be an effective marker for prognosis during treatment of HPV-positive head and neck cancer
Entrectinib Shows Activity in Pediatric Brain Tumors and Other Solid Tumors
Entrectinib showed activity and appeared to be safe in pediatric patients with recurrent or refractory solid tumors harboring NTRK1/2/3, ROS1, or ALK aberrations.
